MustGrow Biologics (CSE: MGRO) this morning reported the results of greenhouse trials with its mustard-derived biopesticide known as TerraMG. Trials were conducted via an independent third party to determine the effectiveness of the formulation against aphanomyces euteiches, which is more commonly known as root rot.
Within the greenhouse trials, plants that were treated with MustGrow’s formulation reportedly demonstrated robust plant and root system health. The disease was found to be controlled by the biopesticide along a range of what have been deemed to be economic application rates.
Soil samples were initially infested with the disease prior to the application of the product. Those plants that were treated with TerraMG reportedly demonstrated increasingly robust results in line with application rates.
The company will now continue to advance the trials of the formulation via larger scale field tests. Field testing, as previously announced, is being conducted with that of NexusBioAg under a collaboration arrangement.
MustGrow Biologics last traded at $1.75 on the CSE.
FULL DISCLOSURE: MustGrow Biologics Corp is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover MustGrow Biologics Corp on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
